<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274933</url>
  </required_header>
  <id_info>
    <org_study_id>M19-992</org_study_id>
    <secondary_id>2019-003452-36</secondary_id>
    <nct_id>NCT04274933</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy</brief_title>
  <official_title>A Phase 1b Study of Venetoclax and Capecitabine In Subjects With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human&#xD;
      epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate&#xD;
      the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-,&#xD;
      metastatic breast cancer (MBC) who had disease progression following treatment that included&#xD;
      a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.&#xD;
&#xD;
      Venetoclax is an investigational drug being developed for the treatment of breast cancer.&#xD;
      This study is open-label meaning both the participants and study doctors will know what&#xD;
      treatment is being given. The study includes two phases: dose escalation and dose expansion.&#xD;
      In dose escalation, participants will receive various doses of venetoclax in combination with&#xD;
      capecitabine. In dose expansion, participants will receive the recommended dose of venetoclax&#xD;
      determined during dose escalation in combination with capecitabine. Adult participants with&#xD;
      locally advanced or MBC that is not amenable to curative therapy will be enrolled. Around 42&#xD;
      participants will be enrolled at approximately 20 sites worldwide.&#xD;
&#xD;
      Venetoclax and capecitabine will be administered on a 21-day cycle. During dose escalation,&#xD;
      participants will take various doses of venetoclax as a tablet by mouth once a day and&#xD;
      capecitabine as a tablet by mouth twice per day on days 1 - 14 of each cycle for&#xD;
      approximately 30 weeks. During dose expansion, participants will take venetoclax at the dose&#xD;
      identified during dose escalation as a tablet by mouth once a day and capecitabine as a&#xD;
      tablet by mouth twice per day on days 1 - 14 of each cycle for approximately 30 weeks.&#xD;
&#xD;
      There may be a higher burden for participants in this trial compared to standard of care.&#xD;
      Participants will attend weekly visits during the course of the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests, and&#xD;
      evaluating for side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company Decision&#xD;
  </why_stopped>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Actual">October 8, 2020</completion_date>
  <primary_completion_date type="Actual">October 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 21 days after first dose of study drug</time_frame>
    <description>Adverse events that are considered by the investigator to have a reasonable possibility of relationship to the administration of venetoclax in combination with capecitabine will be considered a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of venetoclax</measure>
    <time_frame>Up to 9 days after first dose of study drug</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of capecitabine</measure>
    <time_frame>Up to 9 days after first dose of study drug</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of capecitabine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of 5-fluorouracil</measure>
    <time_frame>Up to 9 days after first dose of study drug</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of 5-fluorouracil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (peak time, Tmax) of venetoclax</measure>
    <time_frame>Up to 9 days after first dose of study drug</time_frame>
    <description>Time to Cmax (peak time, Tmax) of venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (peak time, Tmax) of 5-fluorouracil</measure>
    <time_frame>Up to 9 days after first dose of study drug</time_frame>
    <description>Time to Cmax (peak time, Tmax) of 5-fluorouracil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (peak time, Tmax) of capecitabine</measure>
    <time_frame>Up to 9 days after first dose of study drug</time_frame>
    <description>Time to Cmax (peak time, Tmax) of capecitabine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for venetoclax up to 24 hours post-dose (AUC0-24)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Area under the plasma concentration versus time curve for venetoclax up to 24 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for capecitabine/5-fluorouracil up to 12 hours post-dose (AUC0-12)</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>Area under the plasma concentration versus time curve for capecitabine/5-fluorouracil up to 12 hours post-dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: Venetoclax and Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Venetoclax and Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Dose Escalation: Venetoclax and Capecitabine</arm_group_label>
    <arm_group_label>Dose Expansion: Venetoclax and Capecitabine</arm_group_label>
    <other_name>Venclexta</other_name>
    <other_name>ABT-199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Dose Escalation: Venetoclax and Capecitabine</arm_group_label>
    <arm_group_label>Dose Expansion: Venetoclax and Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of advanced or metastatic breast cancer that is hormone receptor positive&#xD;
             (HR+) and HER2 negative (HER2-).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0-1.&#xD;
&#xD;
          -  Willing to provide tissue biopsy sample prior to start of study treatment, and in&#xD;
             participants with measurable disease, at Day 1 of Cycle 3.&#xD;
&#xD;
               -  Escalation cohort: Able to provide a tissue sample obtained at any time in&#xD;
                  disease history prior to start of study treatment.&#xD;
&#xD;
               -  Expansion cohort: Able to provide a fresh tissue sample from either primary tumor&#xD;
                  or metastatic site; if fresh sample collection is deemed unsafe by the&#xD;
                  investigator, then an archival tissue block is acceptable if obtained at time of&#xD;
                  most recent progression and within 16 weeks of study treatment.&#xD;
&#xD;
          -  Experienced disease progression during or after CDK4/6 inhibitor therapy administered&#xD;
             in combination with endocrine therapy for a minimum of 8 weeks prior to progression.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of receiving systemic cytotoxic chemotherapy in the locally advanced or&#xD;
             metastatic setting.&#xD;
&#xD;
          -  Received anti-cancer therapy within the previous 21 days prior to the start of study&#xD;
             drugs.&#xD;
&#xD;
          -  No known uncontrolled metastases to the central nervous system (CNS). Participants&#xD;
             with brain metastases are eligible provided they have shown positive clinical and&#xD;
             radiographic stable disease for at least 4 weeks after definitive therapy and have not&#xD;
             used steroids for at least 2 weeks prior to first dose of study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates, LTD /ID# 215051</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital /ID# 214833</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 214832</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center /ID# 216101</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center /ID# 214886</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania /ID# 216357</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cance /ID# 216059</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Med Ctr /ID# 213852</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center /ID# 214867</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists /ID# 215375</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute /ID# 216120</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg /ID# 214679</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm /ID# 214678</name>
      <address>
        <city>Ulm</city>
        <state>Thueringen</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin /ID# 215287</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen /ID# 217021</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital /ID# 224527</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pan American Center for Oncology Trials, LLC /ID# 216862</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group PSC - Hato Rey /ID# 216904</name>
      <address>
        <city>San Juan</city>
        <zip>00917-3104</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Japan</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Locally Advanced</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Hormone Receptor Positive</keyword>
  <keyword>HER2 Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

